Stock Update (NASDAQ:ONCY): Oncolytics Biotech® Inc. (USA) Presents at the 2015 Immune Checkpoint Inhibitors Meeting

Oncolytics Biotech® Inc. (USA) (NASDAQ:ONCY) today announced that Dr. Giovanni Selvaggi MD, Vice President, Clinical Development, made a presentation titled “REOLYSIN® and Immune Checkpoint Inhibitors: Rationale for Combination Therapy” at the 2015 Immune Checkpoint Inhibitors meeting being held from March 24th to 26th in Boston, MA. The presentation included data from single arm clinical studies in patients with primary glioblastomas or brain metastases (REO 013b) and advanced pancreatic cancer (REO 017), as well as preclinical data.

Highlights of the data presented include:

  • REOLYSIN® inducing the up-regulation of PD-1 and PD-L1 in target tissues in patients with primary glioblastomas or brain metastases, and that this up-regulation is strongly associated with productive reoviral infection (REO 013b);
  • The combination of REOLYSIN® and gemcitabine inducing PD-L1 expression in tumour samples from pancreatic cancer patients (REO 017); and
  • The combination of REOLYSIN®, GM-CSF, anti-PD-1 and anti-CTLA-4 improved survival in immune competent mice versus REOLYSIN® and GM-CSF alone and REOLYSIN® and GM-CSF plus either one of the checkpoint inhibitors alone.

“The anti-PD-1/PD-L1 class of drugs is currently one of the most promising new therapeutic areas in oncology and works by helping the body’s immune system recognize and eliminate tumours,” said Dr. Brad Thompson, President and CEO of Oncolytics. “Higher levels of PD-1 and PD-L1 may improve this class of drugs’ effectiveness. The discovery that PD-1 and PD-L1 are up-regulated or increased in tumours in patients treated with REOLYSIN®, combined with our animal model data findings to this point, may indicate that REOLYSIN® is a potentiator for the entire anti-PD-1/PD-L1 drug class. We intend to immediately incorporate these findings into our clinical program.”

REO 013b (brain) is a U.K. open-label, non-randomized, single-center study of REOLYSIN® given intravenously to patients prior to planned surgery for recurrent high grade primary or metastatic brain tumours in advance of their scheduled operations to remove brain tumours.

REO 017 is a U.S. Phase II single-arm clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in chemotherapy-naïve patients with advanced or metastatic pancreatic cancer.

Shares of Oncolytics closed yesterday at $0.7979 . ONCY has a 1-year high of $2 and a 1-year low of $0.40. The stock’s 50-day moving average is $0.73 and it’s 200-day moving average is $0.66.

On the ratings front, Oncolytics has been the subject of a number of recent research reports. In a report issued on March 18, Needham analyst Chad Messer reiterated a Buy rating on ONCY, with a price target of $1.50, which implies an upside of 88.0% from current levels. Separately, on March 17, Canaccord Genuity’s Neil Maruoka reiterated a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Chad Messer and Neil Maruoka have a total average return of -2.9% and 12.7% respectively. Messer has a success rate of 32.8% and is ranked #3144 out of 3547 analysts while Maruoka has a success rate of 73.7% and is ranked #942

Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer.


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts